Wilding G - Search Results

1

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

Fakih MG, Wilding G, Lombardo J. Fakih MG, et al. Among authors: wilding g. Clin Colorectal Cancer. 2006 Jul;6(2):152-6. doi: 10.3816/CCC.2006.n.033. Clin Colorectal Cancer. 2006. PMID: 16945172

2

A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.

Fora AA, McMahon JA, Wilding G, Groman A, Ma WW, Romano KS, Fakih MG. Fora AA, et al. Among authors: wilding g. Oncology. 2013;84(4):210-3. doi: 10.1159/000346328. Epub 2013 Jan 17. Oncology. 2013. PMID: 23328486 Clinical Trial.

3

A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.

Puthillath A, Mashtare T Jr, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG. Puthillath A, et al. Among authors: wilding g. Crit Rev Oncol Hematol. 2009 Sep;71(3):242-8. doi: 10.1016/j.critrevonc.2008.10.012. Epub 2008 Dec 10. Crit Rev Oncol Hematol. 2009. PMID: 19081732 Clinical Trial.

4

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.

Vaidyanathan G, Groman A, Wilding G, Fakih MG. Vaidyanathan G, et al. Among authors: wilding g. Oncology. 2010;79(1-2):67-71. doi: 10.1159/000319549. Epub 2010 Nov 12. Oncology. 2010. PMID: 21071992

5

Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer.

Puthillath A, Dunn KB, Rajput A, Smith J, Yang G, Wilding GE, Tan W, Gupta B, Fakih MG. Puthillath A, et al. Among authors: wilding ge. Clin Colorectal Cancer. 2007 Nov;6(10):710-5. doi: 10.3816/CCC.2007.n.040. Clin Colorectal Cancer. 2007. PMID: 18039424

6

5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.

Bir A, Tan W, Wilding GE, Lombardo J, Fakih MG. Bir A, et al. Among authors: wilding ge. Oncology. 2007;72(1-2):4-9. doi: 10.1159/000110546. Epub 2007 Oct 30. Oncology. 2007. PMID: 17971679

7

A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.

Fakih MG, Groman A, McMahon J, Wilding G, Muindi JR. Fakih MG, et al. Among authors: wilding g. Cancer Chemother Pharmacol. 2012 Mar;69(3):743-51. doi: 10.1007/s00280-011-1762-1. Epub 2011 Oct 22. Cancer Chemother Pharmacol. 2012. PMID: 22020318 Clinical Trial.

8

Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer.

Fora A, Patta A, Attwood K, Wilding G, Fakih M. Fora A, et al. Among authors: wilding g. Oncology. 2012;82(1):41-7. doi: 10.1159/000333855. Epub 2012 Jan 26. Oncology. 2012. PMID: 22286543

9

Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.

Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG. Angitapalli R, et al. Among authors: wilding ge. Oncology. 2009;76(5):363-8. doi: 10.1159/000210025. Epub 2009 Mar 25. Oncology. 2009. PMID: 19321964

10

Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.

May KS, Khushalani NI, Chandrasekhar R, Wilding GE, Iyer RV, Ma WW, Flaherty L, Russo RC, Fakih M, Kuvshinoff BW, Gibbs JF, Javle MM, Yang GY. May KS, et al. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1193-8. doi: 10.1016/j.ijrobp.2009.03.002. Epub 2009 Jun 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 19540051

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

551 results

Search Page

Filters